Expanding sustainable access to high quality health solutions

Stefan Oschmann
Message from Stefan Oschmann, Vice Chairman of the Executive Board of Merck KGaA, Darmstadt, Germany
We at Merck KGaA, Darmstadt, Germany are truly committed to making a difference through our efforts to promote innovative access to health in low- and middle-income countries. Access to Health (A2H) is a cross-divisional platform through which we work holistically to overcome access barriers in a sustainable manner.
 
An estimated 1.3 billion people have no access to effective and affordable health care. According to the World Health Organization (WHO), developing countries bear 93% of the world’s disease burden, yet account for only 18% of world income and 11% of global health spending. Providing access to health in these countries is a complex challenge*. Improving access involves researching, developing and refining health solutions, creating efficient health systems and distribution channels, offering products at affordable prices and empowering health workers and patients. All health stakeholders, both public and private, must pool their efforts to overcome health access barriers.
Merck KGaA, Darmstadt, Germany is committed to improving the health of underserved populations, who lack access to health solutions including prevention, diagnostics and treatments. We are a leading company for innovative and top-quality high-tech products. As the oldest pharmaceutical and chemical company in the world, founded in 1668, we have developed countless innovations that improve people’s lives across the world, regardless of their ability to pay or geographic location.
Developing countries where Merck KGaA, Darmstadt, Germany helps expand access to health

*Denis Drechsler and Johannes Jütting, Private Health Insurance for the Poor in Developing Countries? 2005

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate under the umbrella brand EMD.
 
  
Read more on M - The Explorer Magazine

Using hamster cells to fight multiple sclerosis

Michel Revel has developed the multiple sclerosis drug Rebif®. He has dedicated his entire career as a researcher to the search for MS treatments.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

The car couturier shows his passion for color

The technology visionary Rainer Buchmann enhances automobiles with pearl luster effect paints containing pigments from our company.

Read more on M - The Explorer Magazine